Cargando…

Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience

BACKGROUND: Patients with glioblastoma multiforme (GBM) require radiotherapy as part of definitive management. Our institution has adopted the use of volumetric arc therapy (VMAT) due to superior sparing of the adjacent organs at risk (OARs) compared to intensity modulated radiation therapy (IMRT)....

Descripción completa

Detalles Bibliográficos
Autores principales: Briere, Tina Marie, McAleer, Mary Frances, Levy, Lawrence B., Yang, James N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414281/
https://www.ncbi.nlm.nih.gov/pubmed/28464840
http://dx.doi.org/10.1186/s13014-017-0810-3
_version_ 1783233342040178688
author Briere, Tina Marie
McAleer, Mary Frances
Levy, Lawrence B.
Yang, James N.
author_facet Briere, Tina Marie
McAleer, Mary Frances
Levy, Lawrence B.
Yang, James N.
author_sort Briere, Tina Marie
collection PubMed
description BACKGROUND: Patients with glioblastoma multiforme (GBM) require radiotherapy as part of definitive management. Our institution has adopted the use of volumetric arc therapy (VMAT) due to superior sparing of the adjacent organs at risk (OARs) compared to intensity modulated radiation therapy (IMRT). Here we report our clinical experience by analyzing target coverage and sparing of OARs for 90 clinical treatment plans. METHODS: VMAT and IMRT patient cohorts comprising 45 patients each were included in this study. For all patients, the planning target volume (PTV) received 50 Gy in 30 fractions, and the simultaneous integrated boost PTV received 60 Gy. The characteristics of the two patient cohorts were examined for similarity. The doses to target volumes and OARs, including brain, brainstem, hippocampi, optic nerves, eyes, and cochleae were then compared using statistical analysis. Target coverage and normal tissue sparing for six patients with both clinical IMRT and VMAT plans were analyzed. RESULTS: PTV coverage of at least 95% was achieved for all plans, and the median mean dose to the boost PTV differed by only 0.1 Gy between the IMRT and VMAT plans. Superior sparing of the brainstem was found with VMAT, with a median difference in mean dose being 9.4 Gy. The ipsilateral cochlear mean dose was lower by 19.7 Gy, and the contralateral cochlea was lower by 9.5 Gy. The total treatment time was reduced by 5 min. The difference in the ipsilateral hippocampal D(100%) was 12 Gy, though this is not statistically significant (P = 0.03). CONCLUSIONS: VMAT for GBM patients can provide similar target coverage, superior sparing of the brainstem and cochleae, and be delivered in a shorter period of time compared with IMRT. The shorter treatment time may improve clinical efficiency and the quality of the treatment experience. Based on institutional clinical experience, use of VMAT for the treatment of GBMs appears to offer no inferiority in comparison to IMRT and may offer distinct advantages, especially for patients who may require re-irradiation.
format Online
Article
Text
id pubmed-5414281
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54142812017-05-03 Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience Briere, Tina Marie McAleer, Mary Frances Levy, Lawrence B. Yang, James N. Radiat Oncol Research BACKGROUND: Patients with glioblastoma multiforme (GBM) require radiotherapy as part of definitive management. Our institution has adopted the use of volumetric arc therapy (VMAT) due to superior sparing of the adjacent organs at risk (OARs) compared to intensity modulated radiation therapy (IMRT). Here we report our clinical experience by analyzing target coverage and sparing of OARs for 90 clinical treatment plans. METHODS: VMAT and IMRT patient cohorts comprising 45 patients each were included in this study. For all patients, the planning target volume (PTV) received 50 Gy in 30 fractions, and the simultaneous integrated boost PTV received 60 Gy. The characteristics of the two patient cohorts were examined for similarity. The doses to target volumes and OARs, including brain, brainstem, hippocampi, optic nerves, eyes, and cochleae were then compared using statistical analysis. Target coverage and normal tissue sparing for six patients with both clinical IMRT and VMAT plans were analyzed. RESULTS: PTV coverage of at least 95% was achieved for all plans, and the median mean dose to the boost PTV differed by only 0.1 Gy between the IMRT and VMAT plans. Superior sparing of the brainstem was found with VMAT, with a median difference in mean dose being 9.4 Gy. The ipsilateral cochlear mean dose was lower by 19.7 Gy, and the contralateral cochlea was lower by 9.5 Gy. The total treatment time was reduced by 5 min. The difference in the ipsilateral hippocampal D(100%) was 12 Gy, though this is not statistically significant (P = 0.03). CONCLUSIONS: VMAT for GBM patients can provide similar target coverage, superior sparing of the brainstem and cochleae, and be delivered in a shorter period of time compared with IMRT. The shorter treatment time may improve clinical efficiency and the quality of the treatment experience. Based on institutional clinical experience, use of VMAT for the treatment of GBMs appears to offer no inferiority in comparison to IMRT and may offer distinct advantages, especially for patients who may require re-irradiation. BioMed Central 2017-05-02 /pmc/articles/PMC5414281/ /pubmed/28464840 http://dx.doi.org/10.1186/s13014-017-0810-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Briere, Tina Marie
McAleer, Mary Frances
Levy, Lawrence B.
Yang, James N.
Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience
title Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience
title_full Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience
title_fullStr Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience
title_full_unstemmed Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience
title_short Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience
title_sort sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414281/
https://www.ncbi.nlm.nih.gov/pubmed/28464840
http://dx.doi.org/10.1186/s13014-017-0810-3
work_keys_str_mv AT brieretinamarie sparingofnormaltissueswithvolumetricarcradiationtherapyforglioblastomasingleinstitutionclinicalexperience
AT mcaleermaryfrances sparingofnormaltissueswithvolumetricarcradiationtherapyforglioblastomasingleinstitutionclinicalexperience
AT levylawrenceb sparingofnormaltissueswithvolumetricarcradiationtherapyforglioblastomasingleinstitutionclinicalexperience
AT yangjamesn sparingofnormaltissueswithvolumetricarcradiationtherapyforglioblastomasingleinstitutionclinicalexperience